Nurse Practitioner Program year 2024 Reported 2022–2024 Source: CMS Open Payments, 2026 publication

Radha Patel

Nurse Practitioner, Acute Care Buena Park, CA Nurse Practitioner

NPI 1326793910 CMS profile 11378714

8219 Santa Inez Way, Buena Park, CA 90620

Open in the dashboard

General payments

$6,854

271 records reported · program years 2022–2024

Research payments

$0

Paid to them · None reported · program years 2022–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Radha Patel of Buena Park, CA is reported in the CMS Open Payments database as having received $6,854 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $3,209 128
2023 General $3,454 138
2022 General $191 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Radha Patel
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Radha Patel were reported at $0. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Radha Patel Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $123 $38–$327 $132
2022 $191 $130 $44–$369 $149
2023 $3,454 $144 $49–$410 $160
2024 $3,209 $146 $48–$433 $164
2025 $0 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2022–2024
  1. Incyte Corporation $439 12 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $412 14 payments
  3. Pfizer Inc. $362 18 payments
  4. Merck Sharp & Dohme Corporation $345 15 payments
  5. Janssen Biotech, Inc. $318 11 payments
  6. AstraZeneca Pharmaceuticals LP $310 14 payments
  7. Celgene Corporation $272 11 payments
  8. Exelixis Inc. $262 7 payments
  9. Gilead Sciences, Inc. $259 9 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $259 9 payments
  11. Other $3,618 151 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2024
  1. Food and Beverage $6,051 262 payments
  2. Education $804 9 payments
Products named General payments · program years 2022–2024
  1. KEYTRUDA $317 14 payments
  2. Nubeqa $258 10 payments
  3. ENHERTU $246 13 payments
  4. MONJUVI $226 10 payments
  5. XTANDI $220 11 payments
  6. XPOVIO $175 7 payments
  7. REBLOZYL $161 6 payments
  8. INQOVI $157 7 payments
  9. Lonsurf $157 7 payments
  10. IMBRUVICA $150 3 payments
  11. Other $5,640 246 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record